EUVIMEDEUVIMED entdecken
Open Access

Assessing Progression of Biologic Therapies Based on Smoking Status in Patients With Crohn’s Disease

Madeline Alizadeh iD, Osman Ali, Raymond K Cross iD

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Madeline Alizadeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Crohn Disease, Smoking, Disease Progression, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Active smoking is a well-established risk factor for developing Crohn’s disease (CD) and negatively impacts overall disease progression. Patients who start or continue smoking after CD diagnosis are at risk for poor outcomes, higher therapeutic requirements, and have higher rates of relapse. However, it remains unclear if the exposure to smoking leads to increased sequencing through treatment therapies, especially biologics.

Methods

The Study of Prospective Adult Research Cohort with IBD (SPARC IBD) registry has been collecting patient-reported outcomes data in real-time, as well as laboratory, endoscopic, and pathologic samples from 17 tertiary referral centers since 2016. In this study, we conducted a retrospective review of the SPARC clinical registry collected between December 2016 and January 2021 from 1 participating site, the University of Maryland School of Medicine’s Inflammatory Bowel Disease Program. A total of 619 patients were enrolled in the SPARC IBD database. Four hundred twenty-five patients with CD were included for initial review of completeness of data; of these, 144 patients were excluded due to missing data on smoking status and/or biologic treatment, resulting in a final cohort of 281 patients. We collected and analyzed baseline demographic and clinical characteristics. The final cohort was categorized into 3 exposure groups: current, former, and never smokers. Our outcome of interest was number biologics used, categorized into 3 groups: 0, 1, or ≥2 biologics.

Results

One hundred seventy-two never smokers, 70 former smokers, and 39 current smokers were identified. Current, former, and never smokers had no statistically significant differences in number of biologics used (ie, biologic sequencing). However, statistically significant independent risk factors for increased sequencing of biologics were identified. These risk factors included female sex, ileocolonic disease location, younger age at diagnosis, and prolonged disease duration; none of these factors remained significant in adjusted analyses.

Conclusion

To date, this is the first study assessing the association of smoking and sequencing of biologics. Although current or former smokers were not found to sequence through more biologics when compared with never smokers, smoking is a well-established risk factor for poor health outcomes, and efforts should be made to counsel patients to quit. Further, additional research must be done to stratify risk to patients based on amount of tobacco exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseSmokingDisease ProgressionBiological ProductsHumansMaleFemaleAdultRetrospective StudiesMiddle AgedRegistriesRisk FactorsBiological TherapyProspective Studies

Stichwörter der Autor:innen

Crohn’s diseasebiologic therapyinflammatory bowel diseasesmoking

Substanzen

Biological Products

Autor:innen und Institutionen

  • Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore MD 21201, USA.

ORCID-Profile: Madeline Alizadeh, Raymond K Cross

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Alizadeh, M., Ali, O., & Cross, R. K. (2024). Assessing Progression of Biologic Therapies Based on Smoking Status in Patients With Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad131

Vancouver

Alizadeh M, Ali O, Cross RK. Assessing Progression of Biologic Therapies Based on Smoking Status in Patients With Crohn’s Disease. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad131

BibTeX
@article{Alizadeh2024,
  author = {Alizadeh, Madeline and Ali, Osman and Cross, Raymond K},
  title = {Assessing Progression of Biologic Therapies Based on Smoking Status in Patients With Crohn’s Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad131}
}
Kostenlos starten →